AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised)
AZN's Enhertu wins its sixth EU indication with a tumor-agnostic approval. Datroway moves closer to a first-line TNBC EU nod following a positive CHMP opinion.
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors
AZN's Enhertu wins its sixth EU indication with a tumor-agnostic approval. Datroway moves closer to a first-line TNBC EU nod following a positive CHMP opinion.
Jefferies names AstraZeneca a top pick ahead of pivotal heart drug readout
Jefferies has reiterated its 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) and named the drugmaker a Franchise Pick, framing an approaching late-stage trial readout as the next major catalyst for the shares. The broker holds a price target of 18,000p, implying upside of around 30% to the current price.
Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note
In the most recent trading session, Astrazeneca (AZN) closed at $185.68, indicating a +1.45% shift from the previous trading day.
Astrazeneca (AZN) Stock Drops Despite Market Gains: Important Facts to Note
Astrazeneca (AZN) concluded the recent trading session at $174.93, signifying a -1.66% move from its prior day's close.
FDA Accepts AstraZeneca's Filing for Expanded Use of Ultomiris
AZN's Ultomiris wins FDA priority review for IgAN, backed by late-stage data showing a 43.4% proteinuria reduction versus placebo.
AstraZeneca Stock Down 7% in 3 Months: Should You Buy, Sell or Hold?
AZN shares fell after a camizestrant setback, but blockbuster drugs, oncology growth and a deep pipeline support long-term targets.
AstraZeneca's Truqap Wins FDA Nod for Prostate Cancer Indication
AZN wins FDA approval to expand Truqap's use in PTEN-deficient prostate cancer, backed by phase III data showing improved outcomes and broader use.
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know
In the most recent trading session, Astrazeneca (AZN) closed at $182.28, indicating a +1.86% shift from the previous trading day.
AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success
AstraZeneca CEO Pascal Soriot said artificial intelligence is helping the company develop medicines faster, identify promising drug targets, and improve the odds of success in costly clinical trials. Soriot said AstraZeneca is using AI tools and partnerships, including its work with Tempus AI and Pathos, to make smarter drug development decisions and accelerate innovation across its pipeline.
Can AstraZeneca's Expanding Cancer Portfolio Sustain Momentum?
AstraZeneca's oncology sales hit $6.8B in first-quarter 2026, fueled by key cancer drugs. New launches and late-stage pipeline assets support growth.
